Protalix BioTherapeutics (PLX) Share-based Compensation (2010 - 2026)
Protalix BioTherapeutics' quarterly Share-based Compensation came in at $532000.0 in Q1 2026, down 1.48% year-on-year from $540000.0 in Q1 2025, and down 27.32% quarter-over-quarter from $732000.0 in Q4 2025.
Protalix BioTherapeutics has reported Share-based Compensation for 17 years, with the latest figure at $532000.0 in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation fell 1.48% year-over-year to $532000.0; the trailing twelve-month figure through Mar 2026 stood at $2.3 million (down 18.6% YoY), and the FY2025 full-year result was $2.3 million, down 29.39% from the prior year.
- Share-based Compensation for Q1 2026 stood at $532000.0, down from $732000.0 in the prior quarter.
- The five-year high for Share-based Compensation was $1.4 million in Q4 2023, with the low at $36000.0 in Q3 2022.
- Average Share-based Compensation over 5 years is $620529.4, with a median of $598000.0 recorded in 2025.
- Year-over-year, Share-based Compensation sank 89.53% in 2022 and soared 1900.0% in 2023.
- Tracing PLX's Share-based Compensation over 5 years: stood at $539000.0 in 2022, then jumped by 153.62% to $1.4 million in 2023, then tumbled by 52.16% to $654000.0 in 2024, then gained by 11.93% to $732000.0 in 2025, then retreated by 27.32% to $532000.0 in 2026.
- The last three Share-based Compensation figures came in at $532000.0 (Q1 2026), $732000.0 (Q4 2025), and $598000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | 532,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 532,000.00 |
| Mar 31, 2026 | 532,000.00 |
| Dec 31, 2025 | 732,000.00 |
| Dec 31, 2025 | 732,000.00 |
| Sep 30, 2025 | 598,000.00 |
| Sep 30, 2025 | 598,000.00 |
| Jun 30, 2025 | 427,000.00 |
| Jun 30, 2025 | 427,000.00 |
| Mar 31, 2025 | 540,000.00 |
| Mar 31, 2025 | 540,000.00 |
| Dec 31, 2024 | 654,000.00 |
| Dec 31, 2024 | 654,000.00 |
| Sep 30, 2024 | 620,000.00 |
| Sep 30, 2024 | 620,000.00 |
| Jun 30, 2024 | 998,000.00 |
| Jun 30, 2024 | 998,000.00 |
| Mar 31, 2024 | 981,000.00 |
| Mar 31, 2024 | 981,000.00 |
| Dec 31, 2023 | 1.37 Mn |
| Dec 31, 2023 | 1.37 Mn |
| Sep 30, 2023 | 720,000.00 |
| Sep 30, 2023 | 720,000.00 |
| Jun 30, 2023 | 248,000.00 |
| Jun 30, 2023 | 248,000.00 |
| Mar 31, 2023 | 546,000.00 |
| Mar 31, 2023 | 546,000.00 |
| Dec 31, 2022 | 539,000.00 |
| Dec 31, 2022 | 539,000.00 |
| Sep 30, 2022 | 36,000.00 |
| Sep 30, 2022 | 36,000.00 |
| Jun 30, 2022 | 175,000.00 |
| Jun 30, 2022 | 175,000.00 |
| Mar 31, 2022 | 836,000.00 |
| Mar 31, 2022 | 836,000.00 |
| Dec 31, 2021 | 418,000.00 |
| Dec 31, 2021 | 418,000.00 |
| Sep 30, 2021 | 344,000.00 |
| Sep 30, 2021 | 344,000.00 |
| Jun 30, 2021 | 375,000.00 |
| Jun 30, 2021 | 375,000.00 |
| Mar 31, 2021 | 816,000.00 |
| Mar 31, 2021 | 816,000.00 |
| Dec 31, 2020 | 1.01 Mn |
| Dec 31, 2020 | 1.01 Mn |
| Sep 30, 2020 | 852,000.00 |
| Sep 30, 2020 | 852,000.00 |
| Jun 30, 2020 | 272,000.00 |
| Jun 30, 2020 | 272,000.00 |
| Mar 31, 2020 | 431,000.00 |
| Mar 31, 2020 | 431,000.00 |
| Dec 31, 2019 | 236,000.00 |
| Dec 31, 2019 | 236,000.00 |
| Sep 30, 2019 | 86,000.00 |
| Sep 30, 2019 | 86,000.00 |
| Jun 30, 2019 | 138,000.00 |
| Jun 30, 2019 | 138,000.00 |
| Mar 31, 2019 | 290,000.00 |
| Mar 31, 2019 | 290,000.00 |
| Dec 31, 2018 | 418,000.00 |
| Dec 31, 2018 | 418,000.00 |
| Sep 30, 2018 | -14,000.00 |
| Sep 30, 2018 | -14,000.00 |
| Jun 30, 2018 | 14,000.00 |
| Jun 30, 2018 | 14,000.00 |
| Mar 31, 2018 | 62,000.00 |
| Mar 31, 2018 | 62,000.00 |
| Dec 31, 2017 | 46,000.00 |
| Dec 31, 2017 | 46,000.00 |
| Sep 30, 2017 | 75,000.00 |
| Sep 30, 2017 | 75,000.00 |
| Jun 30, 2017 | 98,000.00 |
| Jun 30, 2017 | 98,000.00 |
| Mar 31, 2017 | 118,000.00 |
| Mar 31, 2017 | 118,000.00 |
| Dec 31, 2016 | 223,000.00 |
| Dec 31, 2016 | 223,000.00 |
| Sep 30, 2016 | 163,000.00 |
| Sep 30, 2016 | 163,000.00 |
| Jun 30, 2016 | 227,000.00 |
| Jun 30, 2016 | 227,000.00 |
| Mar 31, 2016 | 375,000.00 |
| Mar 31, 2016 | 375,000.00 |
| Dec 31, 2015 | 383,000.00 |
| Dec 31, 2015 | 383,000.00 |
| Sep 30, 2015 | 446,000.00 |
| Sep 30, 2015 | 446,000.00 |
| Jun 30, 2015 | 554,000.00 |
| Jun 30, 2015 | 554,000.00 |
| Mar 31, 2015 | 419,000.00 |
| Mar 31, 2015 | 419,000.00 |
| Mar 31, 2014 | 670,000.00 |
| Mar 31, 2014 | 670,000.00 |
| Dec 31, 2013 | 636,000.00 |
| Dec 31, 2013 | 636,000.00 |
| Sep 30, 2013 | 954,000.00 |
| Sep 30, 2013 | 954,000.00 |
| Jun 30, 2013 | 1.13 Mn |
| Jun 30, 2013 | 1.13 Mn |
| Mar 31, 2013 | 1.37 Mn |
| Mar 31, 2013 | 1.37 Mn |
| Dec 31, 2012 | 1.69 Mn |
| Dec 31, 2012 | 1.69 Mn |
| Sep 30, 2012 | 3.90 Mn |
| Sep 30, 2012 | 3.90 Mn |
| Jun 30, 2012 | 3.90 Mn |
| Jun 30, 2012 | 3.90 Mn |
| Mar 31, 2012 | 129,000.00 |
| Mar 31, 2012 | 129,000.00 |
| Dec 31, 2011 | 156,000.00 |
| Dec 31, 2011 | 156,000.00 |
| Sep 30, 2011 | 92,000.00 |
| Sep 30, 2011 | 92,000.00 |
| Jun 30, 2011 | 127,000.00 |
| Jun 30, 2011 | 127,000.00 |
| Mar 31, 2011 | 242,000.00 |
| Mar 31, 2011 | 242,000.00 |
| Dec 31, 2010 | 395,000.00 |
| Dec 31, 2010 | 395,000.00 |
| Sep 30, 2010 | 142,000.00 |
| Sep 30, 2010 | 142,000.00 |
| Jun 30, 2010 | 151,000.00 |
| Jun 30, 2010 | 151,000.00 |